



OPEN ACCESS

EDITED AND REVIEWED BY
Anick Bérard,
Montreal University, Canada

*CORRESPONDENCE

Rong Jiang,
✉ listening39@163.com
Rui Zhang,
✉ zhangrui@qdu.edu.cn
Jin-Ling Li,
✉ fanglishanghai@163.com

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to
Pharmacoepidemiology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 31 January 2023
ACCEPTED 13 February 2023
PUBLISHED 20 February 2023

CITATION

Liu Y-Y, Qu Y-Y, Wang S, Luo C-J,
Qiu H-L, Li H-T, Yuan P, Wang L, Li J-L,
Jiang R and Zhang R (2023),
Corrigendum: Efficacy and safety of
riociguat replacing PDE-5is for patients
with pulmonary arterial hypertension: A
systematic review and meta-analysis.
Front. Pharmacol. 14:1155631.
doi: 10.3389/fphar.2023.1155631

COPYRIGHT

© 2023 Liu, Qu, Wang, Luo, Qiu, Li, Yuan,
Wang, Li, Jiang and Zhang. This is an
open-access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Yu-Yang Liu^{1†}, Yi-Yang Qu^{1†}, Shang Wang^{1†}, Ci-Jun Luo¹,
Hong-Ling Qiu¹, Hui-Ting Li¹, Ping Yuan¹, Lan Wang¹,
Jin-Ling Li^{1,2*}, Rong Jiang^{1*} and Rui Zhang^{2*}

¹Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China, ²Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China

KEYWORDS

pulmonary arterial hypertension, riociguat, systematic review, meta, analysis, phosphodiesterase-5 inhibitor

A Corrigendum on

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

by Liu Y-Y, Qu Y-Y, Wang S, Luo C-J, Qiu H-L, Li H-T, Yuan P, Wang L, Li J-L, Jiang R and Zhang R (2023). *Front. Pharmacol.* 14:1052546. doi: 10.3389/fphar.2023.1052546

In the published article, there was an error.

A correction has been made to the conclusions of the abstract on page one. This sentence previously stated:

“PAH patients benefit from PDE-5is compared to riociguat, including in hemodynamic parameters, 6MWD, WHO-FC and biomarkers.”

The corrected sentence appears below:

“Compared to PDE5i, PAH patients benefit more from riociguat in hemodynamics, 6MWD, WHO-FC and biomarkers.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.